Composition, form of production and packaging
Tablets are flat, almost white, with a bevel, with an engraving "DECARIS 150" on one side.
levamisole hydrochloride 177 mg,
which corresponds to the content of levamisole 150 mg
Excipients: corn starch, lactose monohydrate, sucrose, talc, povidone, magnesium stearate.
1 PC. - packings of cellular contour (1) - packs cardboard.
Tablets are round, flat, light-orange in color (there may be a darker coloring), with a facet and with risks on one side sharing a quarter, with a faint smell of apricot.
levamisole hydrochloride 59 mg,
which corresponds to the content of levamisole 50 mg
Excipients: corn starch, sodium saccharinate, povidone, talc, apricot flavor, magnesium stearate, sunny yellow sunset dye (E110).
2 pcs. - packings of cellular contour (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2010.
Levamisole is an anthelmintic preparation. Acting on the ganglion-like formations of nematodes, Decaris causes depolarizing neuromuscular paralysis of the membrane of helminth muscles, blocks succinate dehydrogenase, inhibits fumarate dehydrogenase, disrupting the course of bioenergetic processes of helminths. Thus, paralyzed nematodes are removed from the body by normal intestinal peristalsis within 24 hours after taking the drug.
Levamisol when ingested at a dose of 50 mg is rapidly absorbed from the digestive tract. The maximum concentration in the blood plasma is determined on average 1.5-2 hours after taking the drug. Levamisol is subject to intensive metabolism in the liver, its main metabolites are p-hydroxy-levamisole and its glucuronide.
T 1/2 from the body is 3-6 hours. In unchanged form, kidneys release less than 5%, through the intestine less than 0.2% of the administered dose.
- infection with helminths of Ascaris lumbrocoides, Necator and Americanus Ancylostoma duodenale.
Adults receive 1 tablet 150 mg once. Children aged 3 to 6 years (10-20 kg) - 25-50 mg (0.5-1 tablet of 50 mg); children aged from 6 to 10 years (20-30 kg) 50-75 mg (1-1.5 tablets of 50 mg), children aged 10 to 14 years (30-40 kg) - 75-100 mg (1.5- 2 tablets of 50 mg) once.
The drug should be taken after a meal with a little water, in the evening. There is no need for a laxative or special diet. If necessary, taking the drug can be repeated after 7-14 days.
Headache, insomnia, dizziness, palpitations, seizures, dyspepsia (nausea, vomiting, abdominal pain, diarrhea).
There are reports of the development of side effects from the CNS (encephalopathy) 2-5 weeks after taking the drug, as well as allergic reactions (skin rash), convulsions.
In most patients, these events were reversible, and early use of glucocorticosteroid therapy improved the prognosis.
The connection of these symptoms with the reception of Decaris is not entirely convincing. When using large doses or with prolonged therapy, leukopenia, agranulocytosis, tremor can be observed.
- Agranulocytosis caused by drugs (in history);
- children's age till 3 years;
- the period of breastfeeding.
150 mg tablets are not prescribed for children!
With caution: patients with renal and / or liver failure, with oppression of bone marrow hematopoiesis.
PREGNANCY AND LACTATION
The purpose of the drug during pregnancy is possible only if the intended benefit to the mother exceeds the potential risk to the fetus.
If you need to use the drug during breastfeeding, you should decide whether to stop breastfeeding.
APPLICATION FOR FUNCTIONS OF THE LIVER
The drug is administered with caution to patients with renal insufficiency.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
The drug is administered with caution to patients with hepatic insufficiency.
APPLICATION FOR CHILDREN
The drug is contraindicated in children under the age of 3 years.
150 mg tablets are not prescribed for children!
APPLICATION IN ELDERLY PATIENTS
Data on the appointment of Decaris to the elderly are not provided.
During and after taking the drug within 24 hours you should not drink alcohol. There is insufficient evidence that levamisole, used as an anthelminthic agent, depresses the nervous system.
Effect of the drug on the ability to drive and other mechanisms:
due to the fact that when taking the drug may occur transient, mild dizziness should be careful when driving a car or when working with mechanisms throughout the course of treatment.
Symptoms: with the introduction of a large dose of levamisole (over 600 mg), the following signs of intoxication were described: nausea, vomiting, drowsiness, convulsions, diarrhea, headache, dizziness and confusion.
Treatment: with an accidental overdose and if after taking the drug did not pass much time, the stomach is washed. It is necessary to monitor vital body functions and conduct symptomatic therapy.
If there are signs of an anticholinesterase effect, atropine can be administered.
With the simultaneous administration of the drug with alcoholic drinks, disulfiramoid-like phenomena are observed.
Care must be taken when applying Decaris with drugs that affect hematopoiesis.
With simultaneous administration of the drug with coumarin-like anticoagulants, prothrombin time may increase, so it is necessary to adjust the dose of oral anticoagulant. Decaris increases the level of phenytoin in the blood, so when using them at the same time, it is necessary to control the level of phenytoin in the blood.
Decaris can not be used simultaneously with lipophilic preparations, such as carbon tetrachloride, tetrachlorethylene, chanopodium oil, chloroform or ether, since its toxicity can increase.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
Store at a temperature of 15-30 В° C in places inaccessible to children.
Do not use the drug after the expiry date printed on the package.